SK bioscience's L HOUSE manufacturing facility in Andong, North Gyeongsang Province, which recently cleared a World Health Organization Good Manufacturing Practice quality review via a streamlined desk audit. Courtesy of SK bioscience
SK bioscience completed on Thursday a periodic World Health Organization Good Manufacturing Practice (WHO GMP) review through a documentary assessment alone, without an on-site inspection, at its Andong L HOUSE manufacturing facility, the company said.
According to the company, the three-year GMP review covered four WHO prequalification-approved vaccines: influenza vaccines SKYCellflu and SKYCellflu Quadrivalent, varicella vaccine SKYVaricella and typhoid vaccine SKYTyphoid.
WHO GMP inspections typically require visits to production sites to verify manufacturing and quality management systems in person.
For the Andong facility, the review was completed solely through submitted documentation, which SK bioscience said reflects WHO's confidence in the site's operations and quality systems.
